Guardant Health Inc. (GH)
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.49 per share a year ago.
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health: Leveraging Liquid Biopsy Testing Momentum
Guardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing. GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth. Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH's revenue momentum and market outperformance.
Guardant Health, Inc. $GH Shares Bought by Aquatic Capital Management LLC
Aquatic Capital Management LLC increased its position in Guardant Health, Inc. (NASDAQ: GH) by 17.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,576 shares of the company's stock after acquiring an additional 27,612 shares during the period.
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Compared to Estimates, Guardant Health (GH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.62 per share a year ago.
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health: Look For Explosive Revenue Growth Ahead
Guardant Health, Inc. is rated a Buy, driven by explosive growth potential in cancer and multi-disease screening, notably via its Shield blood test. GH's Shield is the first FDA-approved blood test for primary colorectal cancer screening, with rapid early adoption and significant pricing power due to ADLT status. GH's integrated platform, product breadth, and first-mover advantage in blood-based CRC screening position it to take share from Natera and expand into new markets.
